312638-87-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-4-cyclohexyl-4-piperidineMethanol is used as an intermediate in the synthesis of THIQ (C380165), a potent and selective melanocortin subtype-4 receptor agonist. This makes it valuable in the development of medications targeting melanocortin receptors for potential therapeutic applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 624732-70-3 (4-cyclohexylpiperidin-4-yl)-methanol 
• 10462-00-7 4-cyclohexylpiperidine-4-carboxylic acid ethyl ester 
• 852323-82-1 methyl 1-BOC-4-cyclohexyl-4-piperidinecarboxylate 
• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 77-17-8 Normeperidine 
• 4220-08-0 (4-phenyl-piperidin-4-yl)-methanol 

Downstream Products

• 363192-22-7 4-cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester 
• 624732-88-3 4-cyclohexyl-4-(thiazol-2-ylaminomethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 674791-79-8 C₂₁H₃₇NO₃ 
• 674791-77-6 C₂₁H₃₇NO₄ 
• 363192-38-5 C₂₁H₃₉NO₃ 
• 674791-78-7 C₂₁H₃₈FNO₂ 
• 363192-25-0 C₁₉H₃₂N₂O₂*ClH 
• 363192-24-9 C₂₄H₄₀N₂O₄ 
• 312638-88-3 4-cyclohexyl-4-azidomethylpiperidine-1-carboxylic acid tert-butyl ester 
• 312637-48-2 (S)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (S)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(S)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(S)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 852319-26-7 2-amino-3-(4-chlorophenyl)-1-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-propan-1-one 

Relevant academic research and scientific papers

PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY

The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

MELANOCORTIN RECEPTOR AGONISTS

The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Melanocortin receptor ligands

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein preferably R is substituted aryl, W1 is a carbocyclic unit, and W2 is a heteroatom comprising unit.

Melanocortin receptor ligands

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein preferably R is substituted aryl, W is a pendant unit having the formula: -L-Q L is a linking unit, Q is preferably a cyclic hydrocarbyl unit; W1 is preferably a carbocyclic unit and W2 is a heteroatom comprising unit.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1- (4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl) piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist

Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

Substituted piperidines as melanocortin-4 receptor agonists

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.